[Treatment of liver damage during a course of tuberculosis and chronic pulmonary diseases. Necessity of treatment and new trends].
D001663:Bilirubin / Q000097:blood; D002794:Choline / Q000032:analysis / Q000627:therapeutic use; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006710:Homocysteine / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000032:analysis / Q000627:therapeutic use; D008099:Liver / Q000201:enzymology; D008107:Liver Diseases / Q000188:drug therapy* / Q000209:etiology; D008111:Liver Function Tests; D008171:Lung Diseases / Q000150:complications*; D008297:Male; D010538:Peritonitis / Q000150:complications; D010998:Pleurisy / Q000150:complications; D012830:Silicotuberculosis / Q000150:complications; D000637:Transaminases / Q000378:metabolism; D014397:Tuberculosis, Pulmonary / Q000150:complications*; D014805:Vitamin B 12 / Q000627:therapeutic use
D004338:Drug Combinations; D007783:Lactones; D006710:Homocysteine; D000637:Transaminases; D002794:Choline; D014805:Vitamin B 12; D001663:Bilirubin
Sulla terapia del danno epatico in corso di tubercolosi e di pneumopatie croniche. Necessità del trattamento e nuovi orientamenti